Table 2 US FDA-approved secretome targeting drugs

Abiraterone

Androgen deprivation therapy

Prostate cancer

[309]

Aflibercept

Bind VEGF A and B and PGF

Colorectal cancer

[315]

Axitinib

Against VEGR1-3, PDGFRs, c-Kit and FGFRs

Advanced renal cell carcinoma and soft tissue sarcoma

[316, 317]

Bevacizumab

Antibody against vascular endothelial growth factor (VEGF)

Breast, colon and lung cancer

[238]

Cabozantinib

MET and VEGFR2 inhibitor

Renal cancer and hepatocellular carcinoma

[318]

Dacomitinib

EGFRs inhibitor

Metastatic NSCLC

[319]

Enzalutamide

Androgen deprivation therapy

Prostate cancer

[309]

Erdafitinib

FGF receptor (FGFR) inhibitor

Urothelial carcinoma

[320, 321]

Erlotinib

EGFRs inhibitor

NSCLC and pancreatic cancer

[322]

Gefitinib

EGFRs inhibitor

NSCLC

[322]

Lapatinib

EGFRs inhibitor

Breast cancer and NSCLC and pancreatic cancer

[322]

Lenvatinib

Against VEGFR1-3, FGFR1-4, RET, c-kit, and PDGFRα

Thyroid cancer

[323]

Mogamulizumab

Antibody against CCR4

Skin lymphoma

[324]

Oncolytic virus (talimogene laherparepvec)

Expressing GM-CSF to enhance systemic antitumor immune responses

Melanoma

[308]

Osimertinib

EGFRs inhibitor

NSCLC

[322]

Panitumumab

Antibody against endothelial growth factor receptor (EGFR)

Colorectal carcinoma

[325]

Pazopanib

Against VEGR1-3, PDGFRs, c-Kit, and FGFRs

Advanced renal cell carcinoma and soft tissue sarcoma

[316, 317]

Ramucirumab

VEGFR2 inhibitor

Metastatic gastric and gastro-esophageal junction adenocarcinoma

[326]

Regorafenib

TKRs inhibitor, including VEGFR1-3, FGFRs and PDGFRs

Colorectal cancer and hepatocellular carcinoma

[327]

Sorafenib

Sunitinib

Tyrosine kinase receptors (TKRs) inhibitors, that target multiple TKRs, including VEGF receptors (VEGFRs) and PDGF receptors (PDGFRs)

Kidney cancer, renal cell carcinoma and gastrointestinal stromal tumors

[238]

Vandetanib

VEGFR2 and EGFR inhibitor

Medullary thyroid carcinoma

[328]